The Food and Drug Administration approved cemiplimab-rwlc, or Libtayo, from Regeneron (REGN) Pharmaceuticals for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation. This application was granted priority review, the FDA noted.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Early notable gainers among liquid option names on October 1st
- These 3 “Strong Buy” Value Stocks Have over 30% Upside, According to Analysts – 9/30/2025
- Regeneron announces U.S. FDA approved Evkeeza ANGPTL3 antibody
- Positive Outlook on Regeneron Amidst EYLEA Challenges: Strategic Focus on GLP-1 Therapies for Alzheimer’s
- Scholar Rock Stock (SRRK) Puts on the Pounds Despite Muscle Drug Blow